Evogene has partnered with Queensland University of Technology (QUT) in Australia to develop AI-powered small molecule cancer drugs.[1] The collaboration is based on groundbreaking findings from the laboratory of Dr. Mark Adams, which revealed a new treatable cellular detoxification pathway responsible for resistance to the drug cisplatin in lung cancer (NSCLC).[1] The goal is to design new small molecule inhibitors that block this pathway and restore sensitivity to treatment.[1] It combines the advanced computational capabilities of Evogene ChemPass AI™ for generative molecule design with the expertise of Drs. Adams in the biology of cancer cells.[1] The collaboration aims to overcome chemotherapy resistance in lung cancer through a novel therapeutic strategy.[1] dr. Mark Adams said the partnership will accelerate the transition from research to practical results.[1] dr. Evogene's Gabi Tarcic highlighted the combination of biological insights with AI to offer new options to patients with limited treatment options.[1]